The Federal Trade Commission has accused the three largest pharmacy benefit managers of inflating insulin prices and harming consumers, seeking to prohibit profit-driven favoritism among drugs.
F.T.C. officials highlighted that these P.B.M.s, which control 80 percent of prescriptions, have distorted competition and extracted millions from patients in need of lifesaving medications.
This legal action by the F.T.C. marks a significant effort to restore competition in the market, a move that could lead to lower drug prices beyond just insulin.
The support from F.T.C. commissioners emphasizes a push against exploitative practices by major pharmacy benefit managers that have worsened the drug pricing crisis for consumers.
[
Collection
]
[
|
...
]